RESUMEN
O câncer renal é uma moléstia onde a cura é obtida essencialmente através de tratamento cirúrgico em estágios iniciais. A nefroctomia radical pode ser realizada por via aberta ou laparoscópica, sendo que a última associa as vantagens de procedimentos minimamente invasivos. Neste artigo os autores realizam uma revisão extensa da literatura para comparar os resultados da nefrectomia radical aberta (NRA) versus nefrectomia radical laparoscópica (NRL).
Asunto(s)
Humanos , Riñón , Neoplasias Renales , Nefrectomía , LaparoscopíaRESUMEN
PURPOSE: To demonstrate the economical impact of surgical castration in comparison to the medical castration for patients with advanced prostate cancer. MATERIAL AND METHODS: Between January 2001 and December 2001, 32 patients with advanced prostate cancer underwent bilateral sub-capsular orchiectomy at our Hospital. The costs of this procedure were compared to the costs of medical castration with LH-RH analogues. RESULTS: The costs of the surgical procedure were extremely reduced when compared to published data on the medical treatment. Surgical castration did not have any stronger negative impact on the evolution of these patients when compared to medical castration. CONCLUSION: Surgical castration is an efficient and low cost treatment for advanced prostate cancer
RESUMEN
PURPOSE: To demonstrate the economical impact of surgical castration in comparison to the medical castration for patients with advanced prostate cancer. MATERIAL AND METHODS: Between January 2001 and December 2001, 32 patients with advanced prostate cancer underwent bilateral sub-capsular orchiectomy at our Hospital. The costs of this procedure were compared to the costs of medical castration with LH-RH analogues. RESULTS: The costs of the surgical procedure were extremely reduced when compared to published data on the medical treatment. Surgical castration did not have any stronger negative impact on the evolution of these patients when compared to medical castration. CONCLUSION: Surgical castration is an efficient and low cost treatment for advanced prostate cancer.